In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.

The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.

In the United States, where Black inequity has become a focus of diversity efforts, biopharma companies are working hard to recruit and retain individuals from these communities. In fact, the search for such employees and leaders has become so competitive that competition for diverse talent within the industry is now "fierce," as one executive told In Vivo.   

Ripples from the COVID-19 pandemic can be felt across Asia Pacific as investment from foreign firms into the region dropped by 45% from 2019 to 2020, and continued its decline in 2021 to 34%.